London, UK (PRWEB) September 27, 2013
At present, the world cancer diagnostics industry is on the threshold of technological breakthrough, supported by ongoing advancements in tumor diagnosis and therapy, introduction of new specific antigens and advances in research on cancer’s genetic basis. The world cancer diagnostics market is forecast to experience tremendous growth and rapid expansion in the next five years. Expected technological developments in the industry are likely to open many new opportunities in cancer diagnostics, enabling to determine genetic predispositions, detect specific tumors and monitor biological responses to cancer treatment. The rapid market expansion and growing demand for malignancy assays is expected to be spurred by the increase in the elderly population.
Abbott, Becton Dickinson, Epigenomics, Applied Gene Technologies, Panacea Pharmaceuticals, Myriad Genetics and Enzo Biochem are amid the leading companies which are currently active in the global cancer diagnostics market.
In-demand research report “Global Cancer Diagnostics Market 2013 France, Germany, Italy, Japan, Spain, UK, USA Sales Forecasts, Supplier Shares, Competitive Strategies” worked out by Venture Planning Group (VPG) has been recently published by Market Publishers Ltd.
Title: Global Cancer Diagnostics Market 2013 France, Germany, Italy, Japan, Spain, UK, USA Sales Forecasts, Supplier Shares, Competitive Strategies
Published: August, 2013
Price: US$ 32,500.00
Copyright©2012 Vocus, Inc.
All rights reserved